12-Month Lobbying Summary - In-house Corporation

Return to 12-Month Lobbying Activity Search Results

Apotex Inc. / Martin Arès, President, Apotex Canada and Rest of World (ROW)

Registration Summary

Active - Last Updated: 2026-04-27

Who is lobbying?

Apotex Inc. (Address & business activities)

Martin Arès, President, Apotex Canada and Rest of World (ROW)

Responsible officer in previous versions
- Raymond Shelley, President, Apotex Canada

Received government funding or funding expected in current financial year

Business Relationships

Apotex Inc. is not a subsidiary of any other parent companies.

Beneficiaries of the Lobbying Activity

Apotex Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

What is being lobbied?

Subject Matter Details

Details Regarding the Identified Subject Matter
Subject matters	Details	Categories
Health	Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing.	Policies or Program, Regulation
Health, Intellectual Property	Pharmaceutical policy: Ongoing interactions related to increased and sustainable utilization of cost-saving generic and biosimilar medicines, and a predictable and viable business environment for generic medicines.	Policies or Program, Regulation
Health, Research and Development	Pharmaceutical research & development -support for R&D in Canada.	Policies or Program, Regulation

Who is being lobbied?

Government Institutions

Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Immigration, Refugees and Citizenship Canada (IRCC)
Innovation, Science and Economic Development Canada (ISED)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Services and Procurement Canada (PSPC)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

Oral communication
Written communication

Who are the lobbyists?

Senior officers whose lobbying activities represent less than a significant part of their duties

No lobbyists added

Senior officers and employees whose lobbying activities represent a significant part of their duties

Martin Arès, President, Apotex Canada and Rest of World (ROW) | No public offices held
Andrew Casey, VP, Government Affairs & Policy | No public offices held
Chris Fournier, VP Market Access and Government Relations | No public offices held
Francesco Tallarico, Chief Legal Officer | No public offices held

Lobbyists in previous versions
Senior officers and employees whose lobbying activities represent a significant part of their duties
- Raymond Shelley, President, Apotex Canada | No public offices held
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Andrew Casey, VP, Government Affairs & Policy | No public offices held
- Chris Fournier, VP Market Access and Government Relations | No public offices held
- Raymond Shelley, President, Apotex Canada | No public offices held
- Francesco Tallarico, Chief Legal Officer | No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Martin Arès, President, Apotex Canada and Rest of World (ROW) | No public offices held
- Andrew Casey, VP, Government Affairs & Policy | No public offices held
- Chris Fournier, VP Market Access and Government Relations | No public offices held
- Raymond Shelley, President, Apotex Canada | No public offices held
- Francesco Tallarico, Chief Legal Officer | No public offices held

Registration number: 953865-452
View all registrations versions

Monthly Communication Reports

What oral and arranged communications have taken place?

Date	DPOH, Position Title \| Government Institution	Subject Matters
2026-04-27	Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions Innovation, Science and Economic Development Canada (ISED)	Health, Research and Development
2026-04-27	Alex Axiotis-Perez, Deputy Chief of Staff & Director of Operations \| Office of the President of the King's Privy Council for Canada, Minister responsible for Canada-U.S. Trade, Intergovernmental Affairs, Internal Trade, Privy Council Office (PCO) Galen Richardson, Director of Stakeholder Relations \| Office of the President of the King's Privy Council for Canada, Minister responsible for Canada-U.S. Trade, Intergovernmental Affairs and One Canadian, Privy Council Office (PCO)	Health
2026-04-08	Pamela Aung-Thin, Assistant Deputy Minister Health Canada (HC)	Health, Intellectual Property
2026-03-11	Deepa Murthy, Assistant Director Immigration, Refugees and Citizenship Canada (IRCC) Kulvinder Vaid, Program Manager Immigration, Refugees and Citizenship Canada (IRCC) Frances Anne Watt-Gallardo, Assistant Director Immigration, Refugees and Citizenship Canada (IRCC)	Health
2026-02-05	Justine Frame, Policy Advisor \| Minister of Health, Health Canada (HC) Shahad Khalladi, Senior Policy Advisor \| Minister of Health, Health Canada (HC) Sandenga Yeba, Director of Policy & Deputy Chief of Staff \| Office of the Minister of Health, Health Canada (HC)	Health, Intellectual Property
2026-02-04	Rodrigo Arancibia, Sr Director \| Life Sciences, Innovation, Science and Economic Development Canada (ISED) Madeleine Chenette, Member of Parliament House of Commons Guillaume Couillard, Director General Patented Medicine Prices Review Board (PMPRB) Doug Eyolfson, Member of Parliament House of Commons Helena Jaczek, Member of Parliament House of Commons Loris Mirella, Director - Intellectual Property Trade Policy Global Affairs Canada (GAC) Jacques Ramsay, Member of Parliament House of Commons Arianne Reza, Deputy Minister of Public Services and Procurement Public Services and Procurement Canada (PSPC)	Health, Intellectual Property
2026-02-02	Yash Nanda, Policy Advisor \| Policy and Cabinet Affairs, Prime Minister's Office (PMO)	Health, Intellectual Property
2026-01-27	Pamela Aung-Thin, Assistant Deputy Minister \| Health Products and Food Branch, Health Canada (HC)	Health, Research and Development

View all monthly communication reports

Return to 12-Month Lobbying Activity Search Results

Apotex Inc. - Address & business activities

Address:

150 Signet Drive
Toronto, ON M9L 1T9
Canada

Telephone number: 416-749-9300

Contact information in previous versions
- 150 Signet Drive
  Toronto, ON M9L 1T9
  Canada
  
  Telephone number: 416-558-6257
- 150 Signet Drive
  Toronto, ON M9L 1T9
  Canada
  
  Telephone number: 800-268-4623
  
  Fax number: 800-609-9444
- 150 Signet Drive
  Toronto, ON M9L 1T9
  Canada
  
  Telephone number: 416-749-9300
- 150 Signet Drive
  Toronto, ON M9L 1T9
  Canada
  
  Telephone number: 416-749-9300 Ext. 7366
  
  Fax number: 416-401-3835
- 150 Signet Drive
  Toronto, ON M9L 1T9
  Canada
  
  Telephone number: 416-749-9300
  
  Fax number: 416-749-9578
- 150 SIGNET DRIVE
  WESTON, ON M9L 1T9
  Canada
  
  Telephone number: 416-749-9300
  
  Fax number: 416-749-9578

Description of activities:
Apotex is a Canadian-owned pharmaceutical company which researches, develops, manufactures and distributes 300 medicines to the healthcare system and exports these to 115 countries. Apotex's 2012 Research and Development (R&D) budget was $207 million - positioning it in the top 13 companies for all industrial sectors (20% of sales).

Descriptions of the corporation's activity in previous versions:
- Apotex is a Canadian-owned pharmaceutical company which researches, develops, manufactures and distributes 300 medicines to the healthcare system and exports these to 115 countries. Apotex's 2006 Research and Development (R&D) budget was $179 million - positioning it in the top 15 companies for all industrial sectors (20% of sales).
- Apotex is a Canadian-owned pharmaceutical company which researches, develops, manufactures and distributes 260 medicines to the healthcare system and exports these to 115 countries. Apotex's 2005 Research and Development (R&D) budget was $183 million - positioning it in the top 15 companies for all industrial sectors (20% of sales).
- APOTEX S A CANADIAN-OWNED PHARMACEUTICAL COMPANY WHICH RESEARCHES, DEVELOPS, MANUFACTURES AND DISTRIBUTES 260 MEDICINES TO THE HEALTHCARE SYSTEM AND EXPORTS THESE TO 115 COUNTRIES. APOTEX'S 2003 Research and Development BUDGET WAS $153 MILLION - POSITIONING IT IN THE TOP 15 COMPANIES FOR ALL INDUSTRIAL SECTORS (20% OF SALES)
- APOTEX IS A CANADIAN-OWNED PHARMACEUTICAL COMPANY WHICH RESEARCHES, DEVELOPS, MANUFACTURES AND DISTRIBUTES 250 GENERIC MEDICINES TO THE HEALTH CARE SYSTEM AND EXPORTS THESE TO 115 COUNTRIES. APOTEX'S 2003 R&D BUDGET WAS $153 MILLION - POSITIONING IT IN THE TOP 15 COMPANIES FOR ALL INDUSTRIAL SECTORS (20% OF SALES)
- APOTEX IS A CANADIAN-OWNED PHARMACEUTICAL COMPANY WHICH RESEARCHES, DEVELOPS, MANUFACTURES AND DISTRIBUTES 220 GENERIC MEDICINES TO THE HEALTH CARE SYSTEMA ND EXPORTS THESE TO 115 COUNTRIES. APOTEX'S 2003 R&D BUDGET WAS $153 MILLION - POSITIONING IT IN THE TOP 15 COMPANIES FOR ALL INDUSTRIAL SECTORS (20% OF SALES)
- APOTEX IS A CANADIAN-OWNED PHARMACEUTICAL COMPANY WHICH RESEARCHES, DEVELOPS, MANUFACTURES AND DISTRIBUTES 220 GENERIC MEDICINES TO THE HEALTH CARE SYSTEMA ND EXPORTS THESE TO 115 COUNTRIES. APOTEX'S 2002 R&D BUDGET WAS $110 MILLION - POSITIONING IT IN THE TOP 15 COMPANIES FOR ALL INDUSTRIAL SECTORS (20% OF SALES)
- APOTEX IS A CANADIAN-OWNED PHARMACEUTICAL COMPANY WHICH RESEARCHES, DEVELOPS, MANUFACTURES AND DISTRIBUTES 180 GENERIC MEDICINES TO THE HEALTH CARE SYSTEMA ND EXPORTS THESE TO 115 COUNTRIES. APOTEX'S 2001 R&D BUDGET WAS $110 MILLION - POSITIONING IT IN THE TOP 15 COMPANIES FOR ALL INDUSTRIAL SECTORS (20% OF SALES)
- APOTEX IS A CANADIAN-OWNED PHARMACEUTICAL COMPANY WHICH RESEARCHES, DEVELOPS, MANUFACTURES AND DISTRIBUTES 180 GENERIC MEDICINES TO THE HEALTH CARE SYSTEMA ND EXPORTS THESE TO 115 COUNTRIES. APOTEX'S 2000 R&D BUDGET WAS $105 MILLION - POSITIONING IT IN THE TOP 17 COMPANIES FOR ALL INDUSTRIAL SECTORS (20% OF SALES)
- APOTEX IS A CANADIAN-OWNED PHARMACEUTICAL COMPANY WHICH RESEARCHES, DEVELOPS, MANUFACTURES AND DISTRIBUTES 150 MEDICINES TO THE HEALTH CARE SYSTEM AND EXPORTS THESE TO 110 COUNTRIES. APOTEX'S 1997 R&D BUDGET WAS $67.5 MILLION - POSITIONING IT IN THE TOP 15 COMPANIES FOR ALL INDUSTRIAL SECTORS (19.9% OF SALES).
- APOTEX IS A CANADIAN-OWNED PHARMACEUTICAL COMPANY WHICH RESEARCHES DEV ELOPS, MANUFACTURES AND DISTRIBUTES 150 MEDICINES TO THE HEALTH CARE S YSTEM AND EXPORTS THESE TO 110 COUNTRIES. APOTEX'S 1997 R&D BUDGET WAS $67.5 MILLION - POSITIONING IT IN THE TOP 15 COMPANIES FOR ALL INDUST RIAL SECTORS.(19.9% OF SALES)
- APOTEX IS A CANADIAN-OWNED PHARMACEUTICAL COMPANY WHICH RESEARCHES DEVELOPS, MANUFACTURES AND DISTRIBUTES 150 MEDICINES TO THE HEALTH CARE SYSTEM AND EXPORTS THESE TO 110 COUNTRIES. APOTEX'S 1996 R&D BUDGET WAS $55.9 MILLION - POSITIONING IT IN THE TOP 18 COMPANIES FOR ALL INDUSTRIALSECTORS.

Date Modified:: 2026-05-11

Search and menus

Language selection

12-Month Lobbying Summary - In-house Corporation

Apotex Inc. / Martin Arès, President, Apotex Canada and Rest of World (ROW)

Who is lobbying?

Apotex Inc. (Address & business activities)

Received government funding or funding expected in current financial year

Business Relationships

Beneficiaries of the Lobbying Activity

What is being lobbied?

Subject Matter Details

Who is being lobbied?

Government Institutions

Communication techniques

Who are the lobbyists?

Senior officers whose lobbying activities represent less than a significant part of their duties

Senior officers and employees whose lobbying activities represent a significant part of their duties

Senior officers and employees whose lobbying activities represent a significant part of their duties

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

What oral and arranged communications have taken place?